A psychedelics-focused drug development company is officially asking the Food and Drug Administration (FDA) to review an application to approve MDMA as a prescription medication for the treatment of post-traumatic stress disorder (PTSD). The MAPS Public Benefit Corporation (MAPS PBC) announced on Tuesday that it submitted the new drug application (NDA) to FDA, requesting an […]| Marijuana Moment
A new peer-reviewed study in the journal Nature says treatment with MDMA reduced symptoms in patients with moderate to severe PTSD. The Phase 3 trial findings mean federal regulators could consider approving the drug for wider use as soon as next year, says the Multidisciplinary Association for Psychedelic Studies (MAPS), which sponsored the research. “Thanks […]| Marijuana Moment
The Food and Drug Administration has approved Kisunla (donanemab-azbt) injection for the treatment of Alzheimer’s disease.| U.S. Food and Drug Administration